New hope for tough ovarian cancer: CBX-12 trial launches
Disease control
Recruiting now
This study tests a new drug called CBX-12 in 40 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the drug can shrink tumors and to check its safety at two different dose levels. Participants receive the drug once every 21 days.
Phase: PHASE2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:03 UTC